Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be included in the case of:~  * Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2~ * Participants must be 18 years of age or older~ * Have ascites of malignant disease~ * Have symptoms related to ascites~ * Ascites Index above 0.05 (AI ˃ 0.05)~ * Be an English speaking patient or have an interpreter available~ * Be able to understand and comply with all study requirements and the implications of off-label use of intraperitoneal Bevacizumab~ * Have had at least two paracentesis within the last 4 weeks~Exclusion Criteria:~* Patients will be excluded in the case of:~  * Ascites due to non-malignant cause~ * Concurrent treatment with systemic chemotherapy that has a realistic chance of controlling the ascites~ * Concurrent treatment with intraperitoneal Bevacizumab~ * life expectancy of less than 2 weeks~ * A history of bowel perforation or fistula~ * Symptoms or signs suggestive of bacterial peritonitis~ * Child's C cirrhosis~ * Uncontrolled hypertension~ * Surgery within 28 days of catheter treatment~ * Evidence of coagulopathy~ * Symptoms suggestive of bowel obstruction~ * Major surgery, open biopsy or significant traumatic injury within seven (7) days of first study drug--including neurosurgery.~ * Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.~ * Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements~ * Patients who are pregnant or lactating (females of childbearing potential must have a negative pregnancy test prior to participation)~ * Patients with pre-existing 3 + or greater urine dipstick reading proteinuria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eligible patients requiring paracentesis for symptom control (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).